Recent 8-K filings for CELU

• Apr 21, 2026 23:59 UTC other_material materiality 0.75 negative item 1.01item 2.03item 3.03item 5.02item 8.01item 9.01

  Celularity closes $13.3M NexGel asset sale; Helena default notice on $1.97M note

  Closed asset sale to NexGel for $13.3M ($8.3M cash + $5M note), retired ~$13M debt.

• Mar 10, 2026 23:59 UTC other_material materiality 0.80 positive item 1.01item 8.01item 9.01

  Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs

  Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.

• Mar 05, 2026 23:59 UTC leadership materiality 0.60 neutral item 5.02

  Celularity CFO Joseph DosSantos departs; John Sprague named acting CFO

  Joseph DosSantos left as SVP Finance and Acting CFO on Feb 27, 2026 for personal reasons.

• Dec 23, 2025 23:59 UTC debt materiality 0.70 neutral item 1.01item 2.03item 3.02item 8.01item 9.01

  Celularity closes $10M financing with Philip A. Barach; issues senior secured and convertible notes

  Gross proceeds at closing: $10.0M; potential additional $2.0M subject to conditions.

• Dec 05, 2025 23:59 UTC regulatory materiality 0.60 negative item 8.01

  Celularity receives FDA warning letter over Interfyl marketing claims

  FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).

• Oct 28, 2025 23:59 UTC other_material materiality 0.65 neutral item 1.01item 3.02item 5.03item 9.01

  Celularity raises $2M initial tranche in $6.67M private placement of Series A Preferred and warrants

  Series A Preferred shares sold at 90% of stated value; $2M initial tranche closed Oct 24, 2025.

• Sep 03, 2025 23:59 UTC regulatory materiality 0.70 positive item 8.01

  Nasdaq confirms Celularity compliant with listing rule after late 10-Qs; deficiency closed

  Nasdaq notified Celularity on Sept 2, 2025 that it has regained compliance with Listing Rule 5250(c)(1).

• Aug 18, 2025 23:59 UTC other_material materiality 0.85 positive item 1.01item 8.01item 9.01

  Celularity retires all $41.6M senior secured debt via IP sale and license-back deal

  Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.

• Aug 12, 2025 23:59 UTC other_material materiality 0.70 negative item 1.01item 8.01item 9.01

  Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings

  Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.

• Aug 01, 2025 23:59 UTC debt materiality 0.60 neutral item 1.01item 2.03item 3.02item 9.01

  Celularity issues $6.81M promissory note and warrant to investor Lim Kok Thay

  Issued $6,812,230 promissory note to Lim Kok Thay, 2% interest, matures March 21, 2026, secured by all company assets.

• Jul 30, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Celularity raises $2M via private placement of 1.23M shares and warrants

  Issued 1,230,769 shares of common stock and warrants to purchase 1,230,769 shares at $1.625 per unit.

• Jul 22, 2025 23:59 UTC other_material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Celularity raises $1.035M in private placement of 739,286 shares at $1.40/share

  Issue and sale of 739,286 shares of Class A common stock at $1.40 per share for gross proceeds of $1,035,000.

• May 20, 2025 23:59 UTC debt materiality 0.60 neutral item 1.01item 3.02

  Celularity extends convertible note maturity to Aug 15, 2025; issues 100K shares

  Maturity of Convertible Promissory Note (dated March 13, 2024) extended from May 12, 2025 to August 15, 2025.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

3 positive 4 negative 12 neutral

source · CELU on sec.gov